Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JAA-F11-ADC
- Development stage
- Preclinical
- Lead developer
- University at Buffalo
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
JAA-F11-ADC (also known as hJAA-F11-DM1) is a preclinical antibody-drug conjugate (ADC) developed by For-Robin, a spinout of the University at Buffalo, for the treatment of solid tumors, specifically breast cancer (including triple-negative breast cancer) and lung cancer. The ADC consists of hJAA-F11, a humanized IgG1 monoclonal antibody that specifically targets the alpha-linked Thomsen-Friedenreich glycoantigen (TF-Ag-alpha), conjugated to the microtubule inhibitor payload DM1 (maytansine) via a maleimidocaproyl (MC) linker. TF-Ag-alpha is a tumor-associated carbohydrate antigen expressed on approximately 85% of human carcinomas but cryptic on normal tissues, where only the beta-linked form is present. Upon binding to TF-Ag-alpha on the cancer cell surface, JAA-F11-ADC is rapidly internalized, releasing DM1 to disrupt microtubule dynamics, arrest the cell cycle, and induce apoptosis.
- Other names
- Humanized JAA-F11 construct for ADC deliveryHumanized JAA-F11-ADChJAA-F11-ADChJAA-F-11-ADChJAA-F 11-ADC
02
Targets
TUBB (Tubulin (alpha and beta subunits))TF antigen (Thomsen-Friedenreich antigen)
Beyond the preview
Go deeper on JAA-F11-ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JAA-F11-ADC.